Evaluation of outcomes from correction of vitamin D levels in residential care facility residents
A randomised, double-blind, placebo controlled cohort study of the benefits of sufficient levels of vitamin D3 as defined by decreasing the number of fractures, acute illnesses and exacerbation of chronic conditions, the need for hospitalisation as well as the mortality rate for permanent residents of residential care facilities.
ACT Government Health Directorate
250 participants
Sep 19, 2011
Interventional
Conditions
Summary
The Vitamin D study in ACT Residential Care Facilities (RCFs)will examine whether a maintenance dose of vitamin D3 is effective in improving outcomes such as illness presentations, exacerbations of chronic illness, fractures and death in residents of aged care facilities. The main features of this trial are the assessment of 25(OH)D insufficiency and the commencement of the study drug or a placebo while a control group continues on the usual medications prescribed by thier GPs. After treatment with vitamin D3 or placebo for 12 months, the frequency of unplanned GP visits, hospitalisation, falls and mortality will be assessed.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vitamin D3 - Cholecalciferol 1000IU. Unscored white tablet with D3 on one side. Loading dose of 3000IU daily for six weeks, then 1000IU daily taken daily for 12 months. Total trial period is 58 weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000950965